#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Spasticity in Multiple Sclerosis


Authors: M. Kövári
Authors place of work: Klinika rehabilitace a tělovýchovného lékařství 2. LF UK a FN Motol, Praha
Published in the journal: Rehabil. fyz. Lék., 22, 2015, No. 3, pp. 136-139.
Category: Original Papers

Summary

Spasticity is one of the most common symptoms in patients with multiple sclerosis (MS). On one hand, mild spasticity can be desirable symptom, whereas on the other hand high spasticity interferes with voluntary movements of the patient. In therapy we prescribe oral muscle relaxants, but rehabilitation also includes: modulators of endocannabinoid system, local application of botulinum toxin, or implantation of baclofen pump. In this article the author describes the experience of treatment and rehabilitation in MS patients in the Spasticity Center of Motol Hospital.

Keywords:
spasticity, oral muscle relaxants, modulators of endocannabinoid system, botulinum toxin, baclofen pump


Zdroje

1. ASHWORTH, B.: Preliminary trial of carisoprodal in multiple sclerosis. Practitioner, 1964, s. 540-542.

2. ANSARI, N. N., NAGHDI, S., MOAMMERI, H., JALAIE, S.: Ashworth scales are unreliable for the assessment of muscle spasticity. Physiotherapy Theory and Practise, 22, 2006, 3, s. 119-125.

3. BARNES, M. P., KENT, R. M., SEMLYEN, J. K., MC MULLEN, K. M.: Spasticity in multiple sclerosis. Neurorehabil. Neural. Repair, 17, 2003, s. 66-70.

4. BOHANNOM, R. W., SMITH, M. B.: Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys. Ther., 67, 1986, s. 206-207.

5. BORG-STEIN, J., ZACHARY, M. P., MILLER, J. R., MITCHELL, F. B.: Botulinum toxin for the treatment of spasticity in multiple sclerosis. Am. J. Phys. Med. Rehabil., 72, 1993, 6, s. 364-368.

6. DUFEK, M.: Léčba roztroušené sklerózy v České republice – možnosti a realita. Neurologie pro praxi, 15, 2014, 1, s. 31-35.

7. ERWIN, A., GUDESBLATT, M., BETHOUX, F., BENNET, S. E., KOELBEL, S., PLUNKETT, R.: Intrathecal baclofen in multiple sclerosis: too little, too late? Mult. Scler., 17, 2011, s. 623-629.

8. GIOVANELLI, M., BORRIELLO, G., CASTRI, P., PROSPERINI, L., POZZILLI, C.: Early physiotherapy after injection of botulinum toxin increases the beneficial effects on spasticity in patients with multiple sclerosis. Clinical Rehabilitation, 21, 2007, s. 331-337.

9. GOLD, R., OREJA- GUEVARA, C.: Advances in the management of multiple sclerosis spasticity: multiple sclerosis spasticity guideliness. Expert Rev. Neurother., 13, 2013, s. 55-59.

10. GRACIES, J. M., BAYLE, N., VINTI, M., ALKANDARI, S., VU, P., LOCKE, C. M., COLAS, C.: Five step clinical assessment in spastic paresis. European Journal of Physical Rehabil. Med., 46, 2010, 3, s. 411-421.

11. GUSEV, Y., BANACH, M., SIMONOW, A., SKOROMETS, A., CZLONKOWSKA, A., SHMIDT, T. et al.: Efficacy and safety of botulinum type A toxin in adductor spasticity due to multiple sclerosis. Journal of Musculoskeletal Pain, 16, 2008, 3, s. 175-188.

12. HABEK, M., KARNI, A., BALASH, Y., GUREVICH, T.: The place of the botulinum toxin in the management of multiple sclerosis. Clinical Neurology and Neurosurgery, 112, 2010, s. 592-596.

13. HOBART, J. C., RIAZI, A., THOMPSON, A. J., STYLES, I. M., INGRAM, W., VICKERY, P. J., WARNER, M. et al.: Getting the measure of spasticity in multiple sclerosis. The Multiple Sclerosis Spasticity Scale (MSSS-88). Brain, 129, 2006, s. 224-234.

14. HYMAN, N., BARNES, M., BHAKTA, B., COZENS, A., BAKHEIT, M., KRECZY-KLEEDORFER, B. et al.: Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. J. Neurol. Neurosurg. Psychiatry, 68, 2000, s. 707-712.

15. KHALID, A., BARNES, M. P.: A pilot study of a comparison between a patient scored numeric rating scale and clinician scored measures of spasticity in multiple sclerosis. Neuro. Rehabilitation, 24, 2009, s. 333-340.

16. KHEDER, A., PADMAKUMARI, K.: Spasticity: pathophysiology, evaluation and management. Practical Neurology, 12, 2012, s. 289-298.

17. KOLÁŘ, P. et al.: Rehabilitace v klinické praxi. Praha, Galén, 2009, s. 233-246, ISBN 978-80-7262-657-1.

18. NOVOTNÁ, A., MARES, J., RATCLIFFE, S., NOVAKOVA, I., VACHOVA, M., ZAPLETALOVA, O. et al.: A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. European Journal of Neurology, 18, 2011, s. 1122-1131.

19. RAWLINS, P. K.: Intrathecal baclofen therapy over 10 yers. J. Neurosci Nurs, 36, 2004, s. 322-327.

20. RIZO, M. A., HADJIMICHAEL, O. C., PREININGEROVA, J., VOLLMER, T. L.: Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult. Scler., 10, 2004, s. 589-595.

21. SCHWID, S. R., PETRIE, M. D., MURRAY, R., LEITCH, J., BOWEN, J., ALQUIST, A.: A randomized controlled study of the acute and chronic effects of cooling therapy for MS. Neurology, 60, 2003, 12, s. 1955-1960.

22. SZECSI, J., SCHLICK, C., SCHILLER, M., POLLMANN, W., KOENIG, N., STRAIBE. A.: Functional elektrical stimulation- assisted cycling of patients with multiple sclerosis: biomechanical and functional outcome – a pilot study. J. Rehabil. Med., 41, 2009, 8, s. 674-680.

23. ŠTĚTKÁŘOVÁ, I., EHLER, E., JECH, R. et al.: Spasticita a její léčba. Praha, Maxdorf, 2012, s. 247-250, ISBN 978-80-7345-302-2.

24. ŠTĚTKÁŘOVÁ, I., EHLER, E., JECH, R. et al.: Spasticita a její léčba. Praha, Maxdorf, 2012, s. 34, ISBN 978-80-7345-302-2.

Štítky
Physiotherapist, university degree Rehabilitation Sports medicine
Prihlásenie
Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa

#ADS_BOTTOM_SCRIPTS#